Five things for pharma marketers to know: Friday, April 1, 2016
1. GlaxoSmithKline said it will no longer seek patents for drugs sold in 85 low-income countries. The move is expected to help people in those countries have access to less expensive generic versions of their drugs. (WSJ)
2. Sanofi's and Regeneron's dupilumab, an experimental atopic dermatitis treatment, met the primary endpoints in two Phase III clinical trials. The company plans to submit dupilumab to the FDA in the third quarter of this year.
3. The FDA issued guidance recommending that the labels for biosimilars use the same data used by the biologic drugs they are copying. Drugmakers that make biologics have pushed for separate labels for their products and the biosimilar versions of their products. (Modern Healthcare)
4. The rise of autism diagnoses in the U.S. may be leveling off, according to new data from the Centers for Disease Control and Prevention. Saturday is World Autism Awareness Day. (Stat)
5. April Fool's Day came early for Pfizer, Bloomberg reported. A fake press release explaining the company's plan to stop raising prices of its drugs was released, and The Washington Post later had to retract a story. (Bloomberg)